+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07535554

Evaluating the Accuracy of New 18F-AlF-FAPI-74 PETCT Compared to Standard 18F-FDG PETCT in Diagnosing Fever of Unknown Origin, IgG4-Related Disease, and Axial Spondyloarthritis

Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2026-04-17

140

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the diagnostic performance of a new imaging tracer called 18F-AlF-FAPI-74 PETCT in three inflammatory disorders fever of unknown origin FUO, IgG4-related disease IgG4-RD, and axial spondyloarthritis axSpA. This study compares this new tracer with the current standard imaging method, 18F-FDG PETCT, to see if it can provide equal or better results in identifying and assessing these conditions. The study is sponsored by Universitaire Ziekenhuizen KU Leuven and includes both Phase 2 and Phase 3 components. Participants will undergo 18F-AlF-FAPI-74 PETCT scans administered via intravenous injection at the screening visit, with the dose calculated by body weight. The scan involves a low-dose CT with oral contrast after a 60-minute wait post-injection. Patients with IgG4-RD or axSpA who receive treatment will have a follow-up scan three months later to evaluate disease progression or treatment response. The study aims to capture detailed imaging data to compare both tracers effectiveness across the three patient groups. During the study, participants will complete PETCT scans using both the new 18F-AlF-FAPI-74 tracer and the standard 18F-FDG tracer. Researchers will assess diagnostic accuracy, disease extent, and treatment response through various measurements such as uptake values and organ involvement. Follow-up assessments occur up to six months after scans to evaluate outcomes. Safety monitoring includes observation after injection for adverse events. Total participation time varies depending on diagnosis and treatment but includes initial and potential follow-up scans and evaluations.

CONDITIONS

Brief Title

The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.

Research Team

L

Lennert Boeckxstaens, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here